Is Apelin a New Biomarker in Patients With Polycystic Ovary Syndrome?

Ingrid DRAVECKÁ¹, Jana FIGUROVÁ¹, Ivica LAZÚROVÁ¹

¹1st Department of Internal Medicine, Medical Faculty of P. J. Šafarik University, Košice, Slovakia

Received April 21, 2021
Accepted September 7, 2021

Summary
Polycystic ovary syndrome (PCOS) is associated with multiple risk factors for cardiovascular diseases, including insulin resistance, diabetes mellitus type 2, obesity, hypertension, and dyslipidaemia. Many studies have assessed the role of adipokines in the etiopathogenesis of PCOS, however, no single biomarker has been recognized to be in causal relation to the syndrome. Apelin has been identified as a new adipokine linked to obesity and insulin resistance. Some studies demonstrated that the apelin / apelin receptor could play a pivotal role in the pathogenesis of polycystic ovary syndrome, however the other yielded controversial results. Underlying mechanisms of possible involvement of apelin/apelin receptor complex are discussed.

Key words
Polycystic ovary syndrome • Adipokines • Apelin • Reproductive system • Cardiometabolic risk

Corresponding author
Ingrid Dravecká, 1st Department of Internal Medicine, Medical Faculty of P.J. Šafarik University, Košice, Trieda SNP 1, 04011 Košice, Slovakia. E mail: ingrid.dravecka@upjs.sk

Introduction
Polycystic ovary syndrome (PCOS) is the most frequent reproductive endocrinopathy in fertility age women. Although varying among different diagnostic criteria, its frequency ranges about 5-15 % in the reproductive period (Goren et al. 2012, Choi et al. 2012, Olszanecka-Glinianowicz et al. 2013). PCOS is characterized by hyperandrogenic state (clinical and/or biochemical), ovulatory dysfunction, infertility, and polycystic ovarian morphology on ultrasound. Hyperinsulinism and insulin resistance (IR) are common findings in PCOS women, and these traits have cause-consequence relationships with low-grade chronic inflammation and increased early atherosclerosis and cardiovascular disease (CVD) risk. Patients with PCOS have also long-term risks of dyslipidaemia, type 2 diabetes mellitus (T2DM), and endometrial cancer. In addition, more than 50 % of patients have android type of obesity (Goren et al. 2012, Altinkaya et al. 2014). Moreover, women with PCOS exhibit an increased risk of pregnancy complications such as pregnancy-induced hypertension, pre-eclampsia, gestational diabetes, and premature birth (Hasan and Abd El Hammed 2018). Although IR and its metabolic consequences are not included in the diagnostic criteria of PCOS, they are generally accepted to play an important role in the pathogenesis of the disease (Goren et al. 2012).

The pathogenesis of PCOS is still unknown and seems to be multifactorial. Many studies have assessed the role of adipokines in PCOS development (Olszanecka-Glinianowicz et al. 2013). The link between disturbed adipokine secretion and IR in obesity has been established, and IR may represent one of the links between adipokines and polycystic ovaries (Olszanecka-Glinianowicz et al. 2013, Hasan and Abd El Hammed 2018). Adipokines, biologically active peptides secreted from adipose tissue,
are involved in energy homeostasis and metabolism (Goren et al. 2012, Polak et al. 2017). It has been shown that tumour necrosis factor α (TNF-α), interleukin 6 (IL-6), C reactive protein (CRP), insulin-like growth factor 1 (IGF-1), sex steroids, resistin, visfatin, adiponectin, and apelin are associated with IR (Goren et al. 2012). Disturbed secretion of adipokines may also impact the pathophysiology of PCOS through their effect on metabolism and sex steroid secretion (Saleh Ibrahim et al. 2018).

**Apelin**

**Structure and expression of apelin**

Apelin is a bioactive peptide originally identified from bovine stomach extracts as the endogenous ligand for an orphan receptor (APJ) and is found in several organs like heart, brain, kidneys, lungs, and adipose tissue (Goren et al. 2012, Olszanecka-Glinianowicz et al. 2013, Altinkaya et al. 2014, Sun et al. 2015). It appears to exert its effect by binding to the apelin receptor (APLNR) (Liu et al. 2020). APJ is a type of G protein-coupled receptor that was discovered based on its sequence similarly to angiotensin receptor (AT1). Apelin appears to carry out its effect by binding to the angiotensin receptor-like receptor (Liu et al. 2020, Kurowska et al. 2018). Apelin gene encodes a prepropeptide consisting of 77 amino acids, that is released into the circulation in several isoforms including apelin -12, -13, -16, -17, -19 and -36 (Altinkaya et al. 2014, Liu et al. 2020, Kurowska et al. 2018). Shorter forms of apelin (apelin-13) show much higher biological potency than the longer forms (apelin-36) (Kurowska et al. 2018).

**Physiology and pathology of apelin**

Hypothalamus and pituitary gland contain the primary sites of apelin action. In vitro study demonstrated that apelin-13 administration stimulated corticotropin-releasing hormone (CRH) and vasopressin release, suggesting that it may play an important role in the hypothalamic regulation of water intake and endocrine axis (Kurowska et al. 2018). Apelin increases adrenocorticotropic hormone (ACTH) secretion and decreases thyroid stimulating hormone (TSH), prolactin (PRL), follicle stimulating hormone (FSH), and luteinizing hormone (LH) secretion by the pituitary gland (Goren et al. 2012, Olszanecka-Glinianowicz et al. 2013, Altinkaya et al. 2014, Sun et al. 2015).

Moreover, apelin and APLNR are also implicated in several different key physiological processes, such as angiogenesis, cardiovascular system (CVS) in terms of hypotension, fluid homeostasis, cell proliferation, food intake and regulation of energy metabolism (Goren et al. 2012, Altinkaya et al. 2014, Sun et al. 2015, Liu et al. 2020, Kurowska et al. 2018). Apelin was found to be related to obesity and IR and its role in the regulation of glucose homeostasis has been suggested. Insulin stimulates the secretion of apelin, while apelin inhibits insulin secretion and stimulates glucose utilisation (Sun et al. 2015, Kurowska et al. 2018, Nayaker). Low circulating apelin concentrations have been associated with a higher risk of hypertension, especially in Caucasian population (Xie et al. 2017). On the other hand, in the study of Karbek et al. (2014) serum apelin levels were found significantly higher in patients with metabolic syndrome than age-matched control subjects and significantly associated with coronary atherosclerosis. The authors conclude that apelin can be used as a specific marker for insulin sensitivity in patients with metabolic syndrome. Studies in humans have shown an increase in plasma apelin levels in obesity, impaired glucose tolerance (IGT), and T2DM with a reduction in apelin levels accompanying weight loss following diet. These findings suggest the presence of resistance to apelin, in a similar fashion to insulin and leptin (Piya et al. 2013).

**Apelin and reproductive system**

The presence of the apelin system has been demonstrated in the human ovary. Expression of apelin and APNR in granulosa cells and oocytes are significantly increased with ovarian follicle size, decreased at the late luteal phase, and declined sharply during corpus luteum (CL) regression. It is suggested that APLN and APLNR are involved in CL formation, function, and regression during the oestrous cycle. Meanwhile, progesterone has been demonstrated to stimulate the expression of APLNR in granulosa cells (Liu et al. 2020, Kurowska et al. 2018).

Reports regarding serum apelin levels in PCOS are controversial (Hasan et al. 2018, Liu et al. 2020, Nayaker et al. 2017). Apelin may contribute to the PCOS pathogenesis (Karimi et al. 2018). Apelin and APLNR participate in angiogenesis of the luteal phase, which is associated with follicular development. Luteal phase deficiency occurs due to insufficient progesterone produced by CL. A dysfunction of CL results in infertility in PCOS. Hyperlipidaemia and IR result in CL dysfunction and a diminished ability of the CL to produce and secrete progesterone in women with PCOS. Because the
expression of APLNR is stimulated by progesterone, a low level of progesterone might lead to a decrease in APLNR expression (Shirasuna et al. 2008). Recently, some studies have demonstrated that IGF-1 plays a significant role in the regulation and ovarian follicular maturation and steroidogenesis in patients with PCOS (Desai et al. 2015). Roche et al. (2016) in patients with PCOS observed that follicular fluid APLN concentration and granulosa cell APLN and APLNR mRNA expression was higher than that observed in control patients. In cultured human granulosa cells from non-obese patients without PCOS, insulin-like growth factor 1 (IGF1) increased APLNR expression, and recombinant human APLN (APLN-13 and APLN-17) increased both basal and IGF1-induced steroid secretion. IGF-1 promotes the production of oestrogen by stimulating APLN and APLNR. Patients with PCOS have been found to have low oestrogen which is a reason for the increase in APLN/APLNR in follicular fluid. IGF-1 action is modulated by IGFBP-1, which is synthesized in the liver. IGFBP-1 synthesis also occurs in ovarian granulosa cells and endometrium, and its synthesis is inhibited by insulin (Suikkari et al. 1988). The increased insulin levels reduce the synthesis of IGFBP-1, which in turn enhances the bioactivity of IGF-1. IGF-1 could stimulate oestrogen secretion both in granulosa and luteal cells, and IGF-2 stimulates the aromatization of androgens. Therefore, IGF-1 and APLN may exhibit a compensatory increase in PCOS (Hansen et al. 2014). Vascular endothelial growth factor (VEGF) is also critical for ovarian folliculogenesis and normal reproductive function. Serum VEGF concentrations in women with PCOS are significantly higher than those in women with healthy ovaries. VEGF could promote the accumulation of small follicles and increase cyst formation by binding to tyrosine kinase receptors. The APLN/APLNR system functions upstream of VEGF to promote ovarian angiogenesis and to change ovary morphology. However, it was found that hyperinsulinemia could stimulate APLN and VEGF expression: thus, insulin, apelin, and VEGF expression are increased in PCOS (Abd et al. 2005).

Choi and Altinkaya as well as others found that apelin levels were lower in PCOS than in healthy women with a positive correlation with BMI, insulin, HOMA-IR, triglycerides (TG), and free testosterone, speculating that apelin can be used as a marker for insulin sensitivity (Hasan et al. 2018, Polak et al. 2017, Saleh et al. 2018). In the study of Choi et al. (2012), both PCOS groups (with/without hyperandrogenism) had significantly lower serum apelin levels compared with controls. Similarly, in the study of Altinkaya et al. (2014), serum apelin levels were lower in women with PCOS with BMI ≥25 kg/m² than in controls. Lower apelin levels were detected in normal weight women with PCOS as compared with BMI-matched controls. In this study, serum apelin levels were positively correlated with BMI, HOMA-IR, fasting glucose and insulin, TG, and free testosterone levels, but negatively correlated with HDL levels.

On the other side, some authors have found higher plasma apelin concentrations in patients with PCOS compared with healthy controls (Goren et al. 2012, Hasan et al. 2018, Polak et al. 2017, Liu et al. 2020). A study from Egypt demonstrated a significant increase in serum levels of apelin in non-obese and obese PCOS groups when compared to their controls. Within PCOS groups, there were significant positive correlations between apelin and both BMI as well as HOMA-IR (Abd-Elhafez et al. 2020). Either apelin levels in follicular fluid or its expression in granulosa cells were significantly higher in obese than in normal weight women and positively correlated with BMI. In another study, a positive correlation was found between follicle count and both apelin levels in follicular fluid and apelin expression in granulosa cells. Concerning APJ, the authors found the same significant results with a predominant expression of this receptor in the obese group and women with PCOS (Bongrani et al. 2019). On the other hand, APLN expression in follicular fluid was higher than its plasma levels in patients with PCOS, and the APLN concentrations in the follicular fluid were significantly higher in PCOS patients than it was in healthy controls. In addition, APLN and APLN expression in the granulosa cells of PCOS patients was significantly higher than in women without PCOS, and higher in obese PCOS than in non-obese subjects. The authors did not find any significant correlation between plasma apelin levels and biochemical or clinical data in PCOS women as well as control group, except for the negative correlation between apelin and SHBG levels in the control group (Goren et al. 2012).

Some authors reported an inverse association between apelin and glucose, insulin, and HOMA-IR values, supporting the role of apelin in the regulation of insulin sensitivity. Nutritional status seems to have different effects on apelin release in women with PCOS compared to those without PCOS. This may be caused by changes in leptin and resistin secretion and may enhance pituitary-ovarian axis disturbances. There were significantly lower plasma apelin-36 and -12 levels in
obese PCOS patients than those in non-PCOS women. However, plasma apelin-36 and -12 levels were significantly higher in the normal weight PCOS subgroup as compared with the obese group (Olszanecka-Glinianowicz et al. 2013). The meta-analysis of 81 studies showed no significant changes in the circulating levels of apelin in non-obese PCOS relatives to non-obese healthy controls (Lin et al. 2021). Discrepant findings among the published studies may be attributed to differences in ethnicity, age, study design, genetic characteristics, and assessment methodology (Polak et al. 2017).

Apelin and cardiovascular system in PCOS

Being localized in human vascular and endocardial endothelial cells as well as smooth muscle cells of the vascular wall, apelin has been proposed to play a role in the CVS (Akinci et al. 2020). In patients with coronary heart disease apelin concentrations were reported to be lower than healthy controls, suggesting a potential role as an athero-protective factor. Overall, apelin has been described as a beneficial adipokine, and there has been speculation on whether it could be a promising therapeutic target in metabolic disorders and CVD (Aleksandrova et al. 2018). Subclinical atherosclerosis and chronic low-grade vascular inflammation may occur more frequently among women without PCOS. However, it should be noted that the impaired endothelial function has also been observed independent of IR in women with PCOS. Therefore, the increased risk of CVD in women with PCOS might be partially attributed to hyperandrogenism (Kim et al. 2006, Kravariti et al 2005). Choi et al. (2012) investigated serum levels of CVD risk factors including apelin in non-obese women with PCOS. The study suggested that serum apelin levels were positively correlated with apolipoprotein A levels, which were regarded as an athero-protective marker and negatively with total testosterone independent of IR. Serum apelin levels were lower in women with PCOS compared with controls. Despite the presence of CVD risk factors there are currently no adequate prospective outcome data documenting the prevalence of CV events in PCOS. Several studies have established the functional and structural abnormalities of CVS in PCOS (Nayker et al. 2017).

Effect of pharmacologic treatment on serum apelin concentration in PCOS women

Sun et al. (2021) investigated the relevance of apelin and IR and the possible effect of the combined therapy of drospirenone-ethinylestradiol (DRSP-EE) combined with metformin in PCOS women. The PCOS group had higher apelin and fasting insulin levels, and HOMA-IR than the controls. After 3 months of combined treatment, the levels of apelin, testosterone, LH, LH/FSH, and fasting insulin, as well as HOMA-IR, decreased significantly. The levels of fasting glucose, cholesterol, TG, HDL, LDL, and FSH did not change significantly. Serum apelin concentration positively correlated with BMI, fasting insulin level, and HOMA-IR. BMI and HOMA-IR were independent factors related to the level of serum apelin. Less is known about the effect of metformin on serum apelin concentrations. Metformin is a biguanide used in the management of metabolic disorders and insulin resistance in PCOS. Although it may improve commonly associated metabolic and CV risk parameters and restore ovulation in women with PCOS, the effect on apelin levels is still controversial. Hasan and El Hameed (2018) found higher serum apelin levels in obese than lean PCOS women. Metformin treatment improved insulin sensitivity and decreased serum apelin, LH, and testosterone in both groups, although lean patients showed a better response to metformin treatment. These authors confirmed a significant positive correlation between serum apelin levels and BMI, serum insulin level, and HOMA-IR in all PCOS patients before and after metformin treatment.

Probiotics are live microorganisms synergistic with the intestinal microbiota. There is evidence to verify the involvement of intestinal microbiota in IR, obesity, and low-grade inflammation, which are associated with PCOS. Therefore, it can be argued that symbiotic (probiotics and prebiotics) supplementation may potentially reduce the consequences of PCOS. In the randomized double-blind study of Karimi et al. (2018), authors examined the effect of synbiotics on serum apelin concentration and metabolic parameters in PCOS women. A 12 -week symbiotic supplementation had no significant beneficial effects on IR and hs-CRP in women with PCOS, whereas the serum levels of apelin 36 significantly decreased after treatment.

Conclusion

PCOS is the most common endocrine cause of menstrual irregularities, hirsutism, and acne, but its pathogenesis remains unclear. Insulin resistance and compensatory hyperinsulinemia play an important role in the pathogenesis of PCOS. Obesity is observed about 50-70% in patients with PCOS and mostly in the form of android obesity. Android type obesity and an increase in
intraabdominal obesity were also shown in non-obese PCOS patients. Approximately 90% of obese women and 45% of lean women with PCOS have IR.

The apelinergic system was found in the hypothalamus, pituitary, ovaries, and testes, and has paracrine effects to control reproduction both in female and male regulation of their physiology. Apelin inhibits gonadotropin and PRL secretion in females and has a stimulatory effect on steroidogenesis and proliferation but an inhibitory action on cell apoptosis. There are limited data in the literature regarding the change in apelin levels and their relation to IR, obesity, and hormonal disturbances in PCOS. Study results regarding changes in apelin level or its relation to PCOS are inconsistent. Some studies reported lower levels of apelin in PCOS women, however, others reported higher levels. Choi et al. (2012) and Chang et al. (2011) reported a lower apelin level in normal-weight PCOS women than in the control group. These studies also suggest that serum apelin level is negatively correlated with total testosterone level and free androgen index (FAI) independently of IR. In contrast to these findings, other studies reported a higher level of apelin in PCOS than in controls. Similarly, Sun et al. (2015) and Abd-Elhafez et al. (2020) presented significantly higher serum apelin levels in PCOS women compared with controls. Moreover, apelin level was positively correlated with BMI, HOMA-IR, and fasting insulin level. Hasad and El Hameed (2018) showed significantly higher serum apelin levels in PCOS patients compared to lean ones. Higher levels of plasma apelin in PCOS might be related to androgenic obesity, increased WHR, increased adiposity, impairment in LH/FSH interaction, hypothalamo-hypophyseal axis effects and compensatory mechanisms due to the metabolic changes in PCOS. The implication of apelin in the pathogenesis of PCOS seems to be more complicated, involving disturbed synthesis of androgens. Larger studies may also aim to detect apelin levels in all phenotypes of PCOS considering the individual impacts of fat distribution, infertility, and hirsutism.

Conflict of Interest
There is no conflict of interest.

Acknowledgements
This work was supported by Ministry of Health 2019/32-UPJŠ-4. Early diagnosis of cardiovascular disease using new hormonal biomarkers. Solution period: 2019-2022.

References


